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Abstract 20 
 21 
Nuclear-cytoplasmic transport though nuclear pore complexes is mediated by 22 
nuclear transport receptors.  Previous reports suggested that aberrant 23 
nuclear-cytoplasmic transport by mutations or overexpression of nuclear pore 24 
complexes and nuclear transport receptors is closely linked to diseases.  Nup214, a 25 
component of nuclear pore complexes, has been found as chimeric fusion proteins in 26 
leukemia.  Among various Nup214-fusion proteins, SET-Nup214 and DEK-Nup214 27 
were shown to be engaged in tumorigenesis, but their oncogenic mechanism remains 28 
unclear.  In this study, we examined the function of the Nup214-fusion proteins by 29 
focusing on their effects on nuclear-cytoplasmic transport.  We found that 30 
SET-Nup214 and DEK-Nup214 interact with XPO1/CRM1 and NXF1/TAP, which 31 
mediate leucine-rich NES-dependent protein export and mRNA export, respectively.  32 
SET-Nup214 and DEK-Nup214 decreased XPO1-mediated nuclear export of NES 33 
proteins such as cyclin B and proteins involved in the NF-κB signaling pathway by 34 
tethering XPO1 onto nuclear dots where Nup214-fusion proteins are localized.  We 35 
also demonstrated that SET-Nup214 and DEK-Nup214 expression inhibited 36 
NF-κB-mediated transcription by abnormal tethering of the complex containing p65 37 
and its inhibitor, IκB, in the nucleus.  These results implicate that SET-Nup214 and 38 
DEK-Nup214 perturb gene expression regulation through alteration of the 39 
nuclear-cytoplasmic transport system.  40 
  41 
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Introduction 42 
 43 
Biological macromolecules are transported between the nucleus and the cytoplasm in 44 
response to extracellular signals.  Transport of molecules with a molecular mass 45 
greater than 40 kDa does not occur by simple diffusion, but is generally facilitated by 46 
nuclear transport receptors (NTRs) through nuclear pore complexes (NPCs) 47 
embedded in the nuclear envelope (1-3).  Controlled nuclear-cytoplasmic transport 48 
plays important roles in maintaining cellular integrity in eukaryotic cells.  It is 49 
reported that aberrant subcellular localization of some proteins is associated with 50 
various cancer cases (4).  p53 has nuclear localization signal (NLS) and nuclear 51 
export signal (NES), and the accumulation of p53 in the cytoplasm has been reported 52 
to be a prognostic indicator in cancer (5).  Nuclear factor-kappa B (NF-κB) 53 
transcription factor is mainly observed in the cytoplasm in normal cells, whereas in 54 
many cancer cells it is largely localized in the nucleus (6). 55 
In addition to aberrant subcellular localization of proteins in cancer, mutations 56 
of genes encoding NTRs and NPC components are found in various types of cancer 57 
(7).  Mutations of Exportin-5 (XPO5) and Exportin-1 (XPO1)/CRM1, members of 58 
export receptors, (8-10) are found in solid cancer and leukemia, respectively.  Four 59 
nucleoporins, Nup98, Nup214/CAN, Nup358/RanBP2, and Tpr, have been reported to 60 
form chimeric proteins by chromosomal translocations mainly in leukemia (11-15).  61 
Nup214 located at the cytoplasmic filament of NPC interacts with NTRs to control 62 
macromolecular transport.  Set-nup214 and dek-nup214 were identified in acute 63 
undifferentiated leukemia and acute myeloid leukemia (AML), respectively (16, 17), 64 
and recently found in several T cell acute lymphoid leukemia (T-ALL) and AML 65 
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patients (18, 19).  SET-Nup214 is found to bind to the hoxa locus and activate its 66 
expression (20).  Ectopic expression of SET-Nup214 causes expansion of 67 
hematopoietic progenitors (21, 22), and blocks cell differentiation (23).  Expression 68 
of DEK-Nup214 leads to acceleration of protein synthesis (24), cell proliferation (25), 69 
and development of leukemia in mice (26).  However, the detailed functions of these 70 
fusion proteins in leukemogenesis remain unclear. 71 
Nup214 interacts with various NTRs such as Importin-β (IPOB)(27, 28), 72 
Exportin-T (XPOT)(29), XPO1(30), Nuclear RNA export factor 1 (NXF1)/TAP 73 
(31-34), NXF2, and NXF3 (35).  Export of both mRNAs and proteins is severely 74 
reduced when the level of Nup214 expression is decreased (36-38), and ectopic 75 
overexpression of truncated Nup214 causes accumulation of NES proteins in the 76 
nucleus in mammals (39).  On the other hand, in Drosophila, nup214 deletion 77 
enhances export of GFP fused with NES (40).  These results indicate that appropriate 78 
expression of Nup214 is critical for regulated export of macromolecules and that 79 
generation of fusion genes containing Nup214 by chromosomal translocation may 80 
affect the nuclear-cytoplasmic transport system (41).  81 
In previous studies, we and another group reported that both SET-Nup214 and 82 
DEK-Nup214 interact with XPO1.  This interaction causes a change in XPO1 83 
localization and consequently impairs correct localization of an artificial model 84 
protein containing NES (28, 42, 43).  Here, we comprehensively analyzed the effects 85 
of SET-Nup214 and DEK-Nup214 expression on the functions of NTRs and their 86 
cargoes.  We found that SET-Nup214 and DEK-Nup214 interact with NXF1 and 87 
XPO1, and abrogates the XPO1 function to dampen nuclear export of endogenous 88 
NES proteins such as cyclin B and proteins involved in the NF-κB pathway.  In 89 
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addition, we demonstrated that SET-Nup214 and DEK-Nup214 expression inhibited 90 
NF-κB-mediated transcription due to abnormal retention of complexes containing p65 91 
and its inhibitor, I kappa B (IκB), in the nucleus.  These results suggest the 92 
possibility that perturbation of proper nuclear-cytoplasmic shutting of 93 
macromolecules by the expression of the Nup214-fusion proteins lead to various 94 
hematologic disorders.  95 
  96 
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Materials and Methods 97 
 98 
Cell culture and transfection 99 
HeLa cells and HEK293T cells were grown in DMEM supplemented with 10% fetal 100 
bovine serum and penicillin-streptomycin.  For transfection assays, GeneJuice 101 
(Merck KGaA, Germany) (IF assay, luc assay, FRAP assay) or Polyethylenimine, 102 
Linear (MW 25,000) (Polysciences, Inc.) (IP assay, ChIP assay) was used.  103 
 104 
Plasmids  105 
For construction of NTR expression vectors, cDNAs were prepared from total RNA 106 
derived from HeLa and HEK293T cells by revers-transcription with ReverTra Ace 107 
(TOYOBO Co., Ltd, Japan) and oligo dT20.  PCR amplification was performed using 108 
KOD FX (TOYOBO Co., Ltd).  PCR fragments were inserted into pCHA (44).  109 
pCAGGS-HA-XPO1 was made by inserting HA-tagged XPO1 fragment obtained by 110 
PCR using pXHC1 as a template into pCAGGS. pCAGGS-SET-Nup214-3Flag and 111 
pCAGGS-DEK-Nup214-3Flag were made by inserting amplified PCR fragment (C 112 
terminal fragment of Nup214 fused with three Flag-tags) using 113 
pCAGGS-SET-Nup214 as a template, into pCAGGS-SET-Nup214 or 114 
pCAGGS-DEK-Nup214.  For pCAGGS-3Flag-Nup214 (1057-2090) and 115 
pCAGGS-3Flag-SET-Nup214 (1637), Nup214 (1057-2090) and SET-Nup214 (1637) 116 
was digested from pCAGGS-Nup214 (1057-2090) and pCAGGS-SET-Nup214 117 
(1637), and inserted into pCAGGS-3Flag.  pmKate2-C-SET-Nup214 and 118 
pmKate2-C-DEK-Nup214 were constructed by excising pmKate2-C (Evrogen) and 119 
ligated with SET-Nup214 and DEK-Nup214 excised from pCAGGS-SET-Nup214 120 
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and pCAGGS-DEK-Nup214.  pEGFP-C1-NXF1 was constructed by ligation of a 121 
fragment excised from pEGFP-C1 (Clontech Laboratories, Inc.) with NXF1 fragment 122 
generated by PCR using pCHA-NXF1 as a template.  To construct pNF-κB40-firefly 123 
luciferase, Interferon Stimulated Response Element (ISRE) of pISRE-TA-luc 124 
(Clontech Laboratories, Inc.) was removed, and a fragment of NF-κB binding element 125 
from pNF-κB-SEAP (Clontech Laboratories, Inc.) was inserted. To construct 126 
pTA-Renilla luciferase, ISRE of pISRE-TA-luc vector was removed, and the firefly 127 
luciferase region was replaced with a fragment of the Renilla luciferase region, which 128 
was obtained from pRL-SV40 (Promega).  Sequences of all fragments obtained by 129 
PCR were confirmed by sequencing analysis. 130 
 131 
Immunoprecipitation (IP) assay and western blot analysis 132 
IP assays and western blot analyses were performed as described previously (45).  133 
To detect chemiluminescence in western blot analysis, Chemi-Lumi One L (Nacalai 134 
tesque, Inc., Japan) or ImmunoStar LD (Wako Pure Chemical Industries, Ltd., Japan) 135 
was used, and signals were observed using LAS-4000mini (GE Healthcare UK Ltd.), 136 
and processed by Adobe Photoshop Elements (Adobe Systems). 137 
 138 
Immunofluorescence (IF) assay, oligo dT-mediated in situ hybridization, and 139 
Proximity Ligation Assay (PLA) 140 
IF assays were performed as described previously (45).  For DNA staining, 141 
TO-PRO-3 Iodide (Life Technologies) (1:5000) was used.  For IF assays of spleen 142 
sections, sample sections with 2 μm in thickness were examined.  143 
8 
 
Paraffin-embedded sections were deparaffinized and rehydrated in xylene and ethanol.  144 
Samples were autocleaved for 5 min in 10 mM citrate buffer solution.  After washing 145 
with PBS(-), samples were subjected to IF assays.  In situ hybridization using oligo 146 
dT was performed according to the protocol as described previously (46).  PLA was 147 
performed using Duolink In Situ PLA (Sigma-Aldrich Co. LLC) according to the 148 
manufacturer’s instructions after incubation with primary antibodies.  After PLA, 149 
samples were incubated with Alexa 488-conjugated anti-mouse IgG and Alexa 150 
633-conjugated anti-rabbit IgG antibodies for 30 min to observe IκBα and p65, 151 
respectively.  Samples were observed by LSM5Exciter confocal microscope with 152 
Plan-Apochromat 63x objective lens (Carl Zeiss Microscopy GmbH, Germany).  153 
Pictures were processed by ZEN software (Carl Zeiss Microimaging GmbH, 154 
Germany).  Statistical analyses were performed by Student’s t-test. 155 
 156 
RNA extraction and RT-qPCR 157 
Total RNA was extracted using MagExtractor -RNA- (TOYOBO Co., Ltd). The 158 
experimental procedure was as described in the manufacturer’s protocol.  Total RNA 159 
(0.5 μg) was reverse-transcribed by ReverTra Ace (TOYOBO Co., Ltd) and oligo 160 
dT20 for 60 min at 42°C.  For qPCR, Fast SYBR Green Master (Roche Diagnostics 161 
GmbH) was mixed with reverse-transcribed samples and primers, and PCR was 162 
carried out by Thermal Cycler Dice Real Time System (TAKARA BIO Inc. Japan).  163 
Primer sequences used in this study were as follows: for A20, 5’-AAG CTG TGA 164 
AGA TAC GGG AGA-3’ and 5’-CGATGAGGGCTTTGTGGATGAT-3’, for 165 
IκBα/NFKBIA, 5’-CTCCGAGACTTTCGAGGAAATAC-3’ and 166 
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5’-GCCATTGTAGTTGGTAGCCTTCA-3’, and for GAPDH, 167 
5’-AGCCAAAAGGGTCATCATCTC-3’ and 168 
5’-GGACTGTGGTCATGAGTCCTTC-3’.  Statistical analyses were performed by 169 
Student’s t-test. 170 
 171 
ChIP assay  172 
ChIP assays were carried out according to the manual supplemented from Merck 173 
except for sonication buffer used in figure 7D.  Sonication buffer; 640 mM KCl, 30 174 
mM NaCl, 1% Triton X-100, 10 mM EDTA, 20mM Tris-HCl (7.9), and 20% glycerol.  175 
qPCR analysis was performed as described for RT-qPCR.  Primer sequences used in 176 
this study were as follows: for A20, 5’-CAGCCCGACCCAGAGAGTCAC-3’ and 177 
5’-CGGGCTCCAAGCTCGCTT-3’, and for IκBα/NFKBIA, 178 
5’-ATTCAAATCGATCGTGGGAAAC-3’ and 179 
5’-GGGAATTTCCAAGCCAGTCA-3’. 180 
  181 
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Results 182 
 183 
SET-Nup214 and DEK-Nup214 interact with nuclear transport receptors 184 
Nucleoporins can be categorized into three groups; transmembrane nucleoporins, 185 
scaffold nucleoporins, and nucleoporins containing phenylalanine-glycine repeats 186 
(FG-Nups).  Nup214 is one of FG-Nups and interacts with several NTRs through its 187 
FG repeat region.  Because both SET-Nup214 and DEK-Nup214 contain the intact 188 
FG repeat region of Nup214 (Figure 1A), it is possible that these fusion proteins 189 
interact with NTRs.  Indeed, SET-Nup214 and DEK-Nup214 were shown to interact 190 
with XPO1 (42, 43).  To verify whether SET-Nup214 and DEK-Nup214 bind to 191 
several NTRs other than XPO1, we first performed immunoprecipitation (IP) assays.  192 
We assessed seven well-known NTRs as follows; Importin-β1 (IPOB) (import of 193 
NLS-containing proteins), Importin-7 (IPO7) (import of proteins such as histone and 194 
MAPK), XPO1 (export of NES-containing proteins, snRNAs, and snoRNAs), 195 
Exportin-2 (XPO2) /CSE1L (export of Importin α), Exportin-5 (XPO5) (export of 196 
small RNAs), Exportin-3 (XPO3) /Exportin-t (export of tRNAs), and NXF1 (export 197 
of mRNAs).  Among these NTRs, XPO1 and NXF1 bind to SET-Nup214 and 198 
DEK-Nup214 efficiently (Figure 1B).  Because SET-Nup214 and DEK-Nup214 199 
have a shared Nup214 portion (813-2090 a.a.) which is composed of coiled-coil and 200 
FG repeat domains, we addressed whether the binding of SET-Nup214 and 201 
DEK-Nup214 with NTRs was mediated by the Nup214 portion.  The C-terminally 202 
truncated Nup214 (1057-2090) efficiently bound to XPO1 and NXF1 (Figure 1B), 203 
demonstrating the interaction between SET-Nup214 or DEK-Nup214 and XPO1 or 204 
NXF1 depends on the Nup214 part.  Reciprocal IP experiments confirmed the 205 
interaction between SET-Nup214, DEK-Nup214, or Nup214 (1057-2090) and 206 
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endogenous XPO1 or NXF1 (Figure 1C). 207 
 208 
SET-Nup214 and DEK-Nup214 affect subcellular localization of nuclear 209 
transport receptors  210 
As we and another group reported previously (42, 43), SET-Nup214 and 211 
DEK-Nup214 are mainly localized in the nucleus as granular dots and influence 212 
subcellular localization of XPO1.  Because NXF1 was also co-immunoprecipitated 213 
with SET-Nup214 and DEK-Nup214, we next examined subcellular localization of 214 
both NTRs by indirect immunofluorescence (IF) assays.  Endogenous XPO1 was 215 
located in the nucleus and the nuclear envelope, whereas it was localized markedly as 216 
granular dots upon expression of SET-Nup214 and DEK-Nup214 (Figure 1D).  217 
XPO1 localization at the nuclear envelope in cells expressing Nup214 (1057-2090) 218 
was reduced and mainly localized in the nucleus where Nup214 (1057-2090) existed.  219 
Endogenous NXF1 was observed in the nucleus in control cells.  On the other hand, 220 
in cells expressing SET-Nup214, NXF1 was found in nuclear dots where 221 
SET-Nup214 accumulated (Figure 1E), albeit the accumulation was less than XPO1.  222 
In addition, in DEK-Nup214 expressing cells, we could not find clear accumulation of 223 
NXF1 to the sites where DEK-Nup214 was accumulated.  It was previously reported 224 
that the FG repeat region of Nup214 plays crucial roles in binding with NTRs.  225 
Therefore, we next examined the importance of the FG repeat region of the fusion 226 
proteins for the localization changes of XPO1 and NFX1 using the deletion mutant of 227 
SET-Nup214 termed SET-Nup214 (1637), which lacks the FG repeat region of 228 
SET-Nup214.  This mutant neither interacted with nor changed the localization of 229 
both endogenous XPO1 and NXF1 (Figure 1C, lane 10, Figures 1D and 1E).  These 230 
results indicate that expression of SET-Nup214 and DEK-Nup214 affects the 231 
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localization pattern of both XPO1 and NXF1 by their physical interaction through the 232 
FG repeat region of Nup214. 233 
 234 
NES proteins enhance dot formation of SET-Nup214 and DEK-Nup214 235 
SET-Nup214 and DEK-Nup214 induced localization change of XPO1 and NXF1 236 
through their physical interactions (Figure 1).  NES proteins facilitate the interaction 237 
between XPO1 and Nup214 (38, 47, 48).  To address the importance of NES 238 
proteins in the interaction between SET-Nup214 or DEK-Nup214 and NTRs, IP 239 
experiments were performed using cell lysates treated with or without leptomycin B 240 
(LMB), an inhibitor of binding between NES and XPO1(49).  The amount of XPO1 241 
co-immunoprecipitated with SET-Nup214 or DEK-Nup214 was decreased in 242 
LMB-treated cells (Figure 2A).  In addition, granular dots generated by 243 
SET-Nup214 and DEK-Nup214 were decreased in size or disappeared after LMB 244 
addition (Figure 2B).  These results suggest that the interaction of XPO1 and 245 
SET-Nup214 or DEK-Nup214 is under the control of its binding with NES proteins, 246 
and that the interaction between XPO1 and its cargos is indispensable for granular 247 
formation of SET-NUP214 and DEK-Nup214. 248 
 249 
SET-Nup214 and DEK-Nup214 affect subcellular localization of endogenous 250 
proteins harboring NES 251 
As XPO1 was accumulated in nuclear dots in cells expressing SET-Nup214 and 252 
DEK-Nup214 (Figure 1D), it was reasonable to hypothesize that intracellular 253 
availability of XPO1 may be decreased.  We have previously found that EGFP fused 254 
to the NES of cAMP-dependent protein kinase inhibitor (PKI) was accumulated in the 255 
nucleus in cells expressing SET-Nup214 (43).  However, it is not known whether 256 
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subcellular localization of endogenous NES proteins is actually affected by the 257 
expression of both SET-Nup214 and DEK-Nup214.  Hence, we performed IF assays 258 
to observe endogenous XPO1 cargo proteins, IκBα and cyclin B1.  IκBα (Figure 3A) 259 
and cyclin B1 (Figure 3C) were localized mainly in the cytoplasm in cells that did not 260 
express SET-Nup214 or DEK-Nup214.  In contrast, they were uniformly 261 
accumulated in the nucleus upon expression of SET-Nup214 and DEK-Nup214.  262 
Because NF-κB transcription factor p65/RelA binds to IκBα in unstimulated cells, we 263 
examined the localization of p65 in cells expressing SET-Nup214 and DEK-Nup214.  264 
Interestingly, we found that the cytoplasmic localization of p65 was also disturbed by 265 
SET-Nup214 and DEK-Nup214.  Quantitative analyses revealed that the ratio of 266 
fluorescent intensity of IκBα or p65 in the nucleus to that in the cytoplasm was 267 
increased significantly as intensity of SET-Nup214 and DEK-Nup214 increased 268 
(Figure 3A).  When the C-terminal region of Nup214 (Nup214 (1057-2090)) was 269 
expressed, nuclear accumulation of IκBα and p65 was also observed (Figure 3B).  It 270 
indicated that the C-terminal region of Nup214 can function as a dominant negative 271 
mutant of endogenous Nup214 as previously reported (39).  From these observations, 272 
we conclude that SET-Nup214 and DEK-Nup214 change subcellular localization of 273 
endogenous proteins harboring NES by inhibiting the endogenous Nup214 function. 274 
 275 
SET-Nup214 has a small effect on polyA mRNA localization 276 
In addition to XPO1, the expression of SET-Nup214 affected the localization of 277 
NXF1, an NTR for mRNA (Figure 1E).  We assessed subcellular localization pattern 278 
of mRNA by fluorescence in situ hybridization assays using oligo dT as a probe 279 
(Figure 3D).  In control cells, oligo dT signal was observed both in the nucleus and 280 
the cytoplasm, and the cytoplasmic intensity was higher than the nuclear intensity. In 281 
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some of SET-Nup214 expressing cells, the signal intensity ratio of oligo dT in the 282 
nucleus to that in the cytoplasm is higher than that in control cells.  Quantitative 283 
analyses showed that cells highly expressing SET-Nup214 were prone to mRNA 284 
accumulation in the nucleus.  However, the accumulation of mRNAs was less clear 285 
than that of proteins harboring NES, suggesting that the effect of SET-Nup214 on the 286 
NXF1 function is lower than that on the XPO1 functions.  In addition, we found that 287 
there was little difference of oligo dT staining pattern in control cells and cells 288 
expressing DEK-Nup214.  289 
 290 
SET-Nup214 and DEK-Nup214 reduce the mobility of XPO1 291 
Fluorescence Recovery After Photobleaching (FRAP) analyses have shown that 292 
XPO1 is highly mobile in the cell (50).  As XPO1 is localized as granular dots in 293 
cells expressing SET-Nup214 and DEK-Nup214, it was possible that the XPO1 294 
mobility was decreased.  To test this, we performed FRAP assays for fluorescent 295 
protein-fused XPO1 (51), SET-Nup214, and DEK-Nup214.  Expression of 296 
fluorescent proteins was confirmed by western blot analyses and immunofluorescence 297 
microscopy (Figures 4A and B).  The area indicated by white square was bleached 298 
with 488 nm laser line, and intensity of the bleached area was monitored every 2 299 
seconds. In control cells, the EGFP-XPO1 fluorescent intensity in the bleached area 300 
was restored rapidly after bleaching.  On the other hand, EGFP-XPO1 was 301 
accumulated in the dots, and the recovery rate of fluorescence in the dots (indicated as 302 
yellow circle in Figure 4C) was significantly reduced by the co-expression of 303 
mKate2-SET-Nup214 and mKate2-DEK-Nup214.  The intensity of 304 
mKate2-SET-Nup214 and mKate2-DEK-Nup214 after photobleaching was not 305 
efficiently recovered, and only a small fraction was recovered in 80 seconds (Figure 306 
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4C).  These results indicate that SET-Nup214 and DEK-Nup214 in the dots are not 307 
exchangeable efficiently, but rather form stable complexes/aggregates to which XPO1 308 
is attracted.  309 
 310 
SET-Nup214 and DEK-Nup214 affect NF-κB transcription activity 311 
We presumed that a cause of oncogenesis by the expression of SET-Nup214 and 312 
DEK-Nup214 is due at least in part to the deregulation of gene expression caused by 313 
aberrant localization of proteins and/or RNAs.  Subcellular localization of p65 and 314 
IκBα was changed upon expression of SET-Nup214 and DEK-Nup214 (Figure 3A).  315 
It was reported Nup98-fusion proteins stimulate NFAT- and NF-κB-mediated 316 
transcription activities by impairing the XPO1 function (52).  Thus, we examined the 317 
effect of these Nup214-fusion proteins on the NF-κB signaling pathway.  The 318 
transcriptional activity of NF-κB was assessed first by reporter assays using firefly 319 
luciferase under the control of NF-κB (κB-FLuc).  In the absence of TNF-α, the 320 
fusion proteins did not affect the luciferase activity (Figure 5A-C, left graphs), 321 
although the fusion proteins induced nuclear accumulation of p65 (Figure 3A).  322 
TNF-α treatment dramatically increased the reporter activity of κB-FLuc.  This 323 
increase of the transcriptional activity was markedly inhibited by the expression of 324 
SET-Nup214 and DEK-Nup214 (Figure 5A-C, right graphs).  As reported (53) (54) 325 
(55), LMB treatment showed an inhibitory effect on the luciferase activity of 326 
NF-κB-mediated transcription in the presence of TNF-α (Figure 5A-C, right graphs), 327 
while no significant effect was observed in the absence of TNF-α (Figure 5A-C, left 328 
graphs).  The effects of SET-Nup214 and DEK-Nup214 expressions on the 329 
pTA-Renilla luciferase reporter under the control of the minimal promoter 330 
(TATA-RLuc) was less clear than those on the κB-luciferase activity, suggesting that 331 
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the effect of the expression of SET-Nup214 and DEK-Nup214 on the 332 
NF-κB-mediated transcription was specific.  We next evaluated the effect of 333 
SET-Nup214 and DEK-Nup214 on the transcription of endogenous NF-κB target 334 
genes A20 and IκBα by RT-qPCR.  Consistent with the reporter assays above, 335 
set-nup214 and dek-nup214 diminished the mRNA amounts of A20 and IκBα in a 336 
dose-dependent manner (Figure 5D).  Collectively, these results demonstrate that 337 
SET-Nup214 and DEK-Nup214 impair the NF-κB transcription activity and this 338 
impairment occurs when the NF-κB signaling pathway is activated. 339 
 340 
SET-Nup214 and DEK-Nup214 induce nuclear accumulation of the p65-IκBα 341 
complex in the absence of stimulus 342 
In unstimulated cells, the majority of NF-κB transcription factors such as p65 and p50 343 
interact with IκB.  As p65 and p50 have NLS, and IκBα has NLS and NES, the 344 
NF-κB-IκBα complex shuttles between the nucleus and the cytoplasm in an 345 
XPO1-dependent manner and is mainly observed in the cytoplasm (53, 54, 56) (6, 55, 346 
57, 58).  In cells expressing SET-Nup214 and DEK-Nup214, the NF-κB 347 
transcription activity remained inactive (Figure 5C, left graph), despite p65 being 348 
located in the nucleus (Figure 3A).  As IκBα is also localized in the nucleus, we 349 
hypothesized that the interaction between p65 and IκBα was maintained in the 350 
nucleus, and thus NF-κB was kept inactive.  To test this, we performed in situ 351 
proximity ligation assays (PLA) and IP assays (Figures 6A and B).  In control cells, 352 
p65 and IκBα were observed in the cytoplasm, and cytoplasmic PLA signals were 353 
detected, indicating the proximity of p65 and IκBα in the cytoplasm.  When cells 354 
were transfected with set-nup214 or dek-nup214, both p65 and IκBα were found in 355 
the nucleus (Figure 3A), and nuclear PLA signals were observed in these cells (Figure 356 
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6A).  By IP assays, p65 was found to interact with IκBα, and this interaction was not 357 
affected by the absence or presence of SET-Nup214 and DEK-Nup214 (Figure 6B).  358 
These results suggest that SET-Nup214 and DEK-Nup214 induce nuclear 359 
accumulation of the p65-IκBα complex, but that the NF-κB signaling pathway was 360 
kept inactive, as the fusion proteins did not affect the interaction between p65 and 361 
IκBα.  Binding of IκBα to p65 causes a release of p65 from DNA (59).  Therefore, 362 
it was presumed that nuclear p65 bound by IκBα in the presence of SET-Nup214 and 363 
DEK-Nup214 could not bind to the target gene promoter.  To confirm this notion, 364 
we performed chromatin immunoprecipitation assays.  The level of p65 that bound 365 
to A20 and IκBα promoter regions was increased by TNF-α treatment. However, p65 366 
binding to these promoters was not enhanced by SET-Nup214 and DEK-Nup214 367 
(Figure 6C), although p65 was localized in the nucleus (Figure 3A).  These results 368 
support our notion that p65 was kept inactive in cells expressing SET-Nup214 and 369 
DEK-Nup214. 370 
 371 
p65-IκBα complex is kept in the presence of stimulus in cells expressing 372 
SET-Nup214 or DEK-Nup214  373 
Reporter assays and RT-qPCR showed that SET-Nup214 and DEK-Nup214 374 
down-regulate the NF-κB transcription activity in the presence of TNF-α (Figure 5C, 375 
right graph).  IκBα is phosphorylated in the cytoplasm upon stimulation, followed 376 
by degradation by the ubiquitin proteasome system (60).  NF-κB transcription 377 
factors are then freed from IκB, localized in the nucleus, and execute target gene 378 
transcription.  We predicted that NF-κB-IκBα complex is maintained by the 379 
expression of SET-Nup214 and DEK-Nup214 even after TNF-α addition.  To test 380 
this, the localization pattern of IκBα and p65 was monitored, and PLA and 381 
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co-immunoprecipitation assays were performed.  After addition of TNF-α, IκBα in 382 
the cytoplasm of both control and SET-Nup214- and DEK-Nup214-expressing cells 383 
was markedly reduced (Figure 7A), indicating degradation of cytoplasmic IκBα.  On 384 
the contrary, IκBα in the nucleus of SET-Nup214- and DEK-Nup214-expressing cells 385 
was visible after TNF-α treatment (Figure 7A).  Restored expression level of IκBα 386 
by SET-Nup214 and DEK-Nup214 was also confirmed by western blotting analysis 387 
(Figure 7C, lanes 1-6).  In cells expressing nuclear p65 and IκBα, PLA signals were 388 
detected both 0 and 30 minutes after TNF-α treatment, demonstrating that the 389 
interaction between p65 and IκBα was maintained in the nucleus after stimulation 390 
(Figure 7B).  The p65-IκBα complex formation in stimulating cells expressing 391 
SET-Nup214 or DEK-Nup214 was confirmed by IP assay (Figure 7C, lanes 7-13).  392 
Finally, to examine whether the recruitment of p65 to its target genes was affected by 393 
SET-Nup214 or DEK-Nup214, ChIP assay was performed.  It was demonstrated that 394 
p65 binding to the A20 and IκBα promoter regions was impaired in the presence of 395 
SET-Nup214 or DEK-Nup214 (Figure 7D).  These results indicate that 396 
nuclear-localized IκBα induced by SET-Nup214 and DEK-Nup214 is escaped from 397 
its phosphorylation and degradation and keeps p65 inactive. 398 
 399 
Subcellular localization of XPO1 and its cargos in set-nup214 transgenic mice 400 
Previously, we generated a transgenic mouse expressing set-nup214 (22). Although 401 
this mouse did not develop leukemia, it shows severe anemia and a halt in 402 
hematopoietic differentiation, both of which are frequently associated with leukemia.  403 
In order to understand the biological relevance of the results obtained from in vitro 404 
cell culture studies, we assessed the localization pattern of XPO1 and its cargos using 405 
spleen sections from set-nup214 transgenic mice.  We observed that SET-Nup214 406 
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and XPO1 are co-localized in the nucleus as granular dots (Figure 8A).  In addition, 407 
it was found that IκBα (Figure 8B) and p65 (Figure 8C) are also localized in the dots.  408 
These results demonstrate that the localization pattern of XPO1 is affected and its 409 
function could be impaired by SET-Nup214 in vivo as well.  410 
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Discussion 411 
 412 
Interaction of SET-Nup214 and DEK-Nup214 with XPO1 and NFX1 413 
In this study, we examined the function of SET-Nup214 and DEK-Nup214 in terms of 414 
their effects on nuclear-cytoplasmic transport of proteins and RNAs.  We found that 415 
among several NTRs, SET-Nup214 and DEK-Nup214 interact preferentially with not 416 
only XPO1 but also NXF1 (Figure 1B).  These interactions were dependent on the 417 
FG repeat region of SET-Nup214 and DEK-Nup214 (Figure 1C).  It is shown that 418 
each FG-Nup binds with different affinity to some of the NTRs, which contain 419 
multiple binding sites for FG-repeats (61, 62).  Hence, it is supposed that the 420 
affinities of the FG repeat region of SET-Nup214 and DEK-Nup214 to NTRs are also 421 
to be varied, and the affinity difference generates binding preference.  Nup214 422 
interacts with XPO1 rather than Xpo-t, NXF1, or XPO2/CAS (29, 63).  Among 423 
various NTRs, ectopic expression of truncated Nup214 containing FG repeat region 424 
has an inhibitory effect on subset of NTRs functions including XPO1 (39).  Our 425 
results are consistent with previous ones, and imply that the SET and DEK portions of 426 
the SET-Nup214 or DEK-Nup214 do not affect the structure and function of Nup214 427 
portion for association with NTRs.  428 
 429 
Effects of SET-Nup214 and DEK-Nup214 on the functions of XPO1 and NXF1  430 
We have demonstrated that SET-Nup214 and DEK-Nup214 associate with both 431 
XPO1 and NXF1.  However, the effect of Nup214-fusion proteins on XPO1 function 432 
was different from that on NXF1.  We showed that SET-Nup214 and DEK-Nup214 433 
induce lower mobility of XPO1 and cause accumulation of XPO1 cargos in the 434 
nucleus (Figures 3A, C, and 4C).  In contrast, mRNA, which is an NXF1 cargo, was 435 
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not accumulated in the nucleus of cells expressing SET-Nup214 and DEK-Nup214 436 
(Figure 3D).  XPO1 was mainly incorporated in the dots where SET-Nup214 and 437 
DEK-Nup214 are located, whereas nuclear-diffused NXF1 was observed in cells 438 
expressing SET-Nup214 and DEK-Nup214 (Figures 1D and E).  This differential 439 
localization of XPO1 and NXF1 in cells expressing SET-Nup214 and DEK-Nup214 440 
could explain the different effects of SET-Nup214 and DEK-Nup214 on the XPO1 441 
and NXF1 functions.  It is assumed that SET-Nup214-XPO1 and 442 
DEK-Nup214-XPO1 complexes could be more stable than SET-Nup214-NXF1 and 443 
DEK-Nup214-NXF1 complex.  444 
 445 
SET-Nup214 and DEK-Nup214 form stable complexes with XPO1 446 
A question is raised as to how SET-Nup214 and DEK-Nup214 can form a stable 447 
complex with XPO1 to induce accumulation of NES proteins in the nucleus.  The 448 
interaction between Nup214 and XPO1 is stabilized when both RanGTP and NES 449 
proteins are incorporated (38, 47, 48).  Consistent with this, we found that inhibition 450 
of the interaction between XPO1 and NES proteins by LMB leads to disappearance of 451 
dots formed in the presence of SET-Nup214 and DEK-Nup214 (Figure 2).  From 452 
these results, we speculate that the nuclear dots are formed by the quaternary stable 453 
complex containing SET-Nup214 or DEK-Nup214, NES proteins, XPO1, and 454 
RanGTP.  Furthermore, it is possible that other proteins play roles in the dot 455 
formation.  Complex formation of RanGTP-XPO1-NES proteins is enhanced by 456 
Nup98 (64) and RanBP3 (65) (66) (67).  Nup214 functions as a scaffold for the 457 
recruitment of several nucleoporins such as Nup88, Nup358, Nup62, and Nup98 (68) 458 
(38) (40, 69).  These proteins may facilitate stable complex formation induced by 459 
SET-Nup214 and DEK-Nup214.  In spleen cells, these dots are much larger than 460 
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those in cultured cells.  It is likely that high expression of proteins constituting these 461 
dots in mouse spleen enlarges the SET-Nup214 nuclear dots.  462 
 463 
Deregulation of transcription by SET-Nup214 and DEK-Nup214 and 464 
oncogenesis 465 
We found that IκBα is localized in the nucleus regardless of the presence or absence 466 
of TNF-α (Figure 7A) in cells expressing SET-Nup214 and DEK-Nup214.  It is 467 
presumed that nuclear-accumulation of IκBα is escaped from IKKβ-mediated 468 
phosphorylation after TNF-α addition, and thus the NF-κB transcription activity is 469 
repressed by the interaction with IκBα  in the nucleus.  In general, NF-κB induces 470 
transcription of various genes related to inflammation, cell proliferation, invasion, and 471 
so on.  NF-κB inactivation is known to counteract oncogenesis or tumorigenesis and 472 
NF-κB is an efficient therapeutic target for cancer (70) (71).  In contrast, NF-κB has 473 
also been reported to have anti-oncogenic activities, such as induction of cellular 474 
senescence.  p65-/- MEFs bypass senescence (72), and p65-downregulated mouse 475 
lymphoma become chemoresistance by escape of senescence (73).  SET-Nup214 476 
and DEK-Nup214 impair the NF-κB pathway (Figure 5).  On this line, it is 477 
speculated that SET-Nup214 and DEK-Nup214 may promote to bypass senescence 478 
via suppression of the NF-κB signaling pathway.  In addition, several studies have 479 
documented the importance of the NF-κB pathway for hematopoiesis.  Conditional 480 
knockout of IKKβ gene upregulates IL-1 production and stimulates proliferation of 481 
neutrophil progenitor, leading to neutrophilia and splenomegaly (74) (75).  In 482 
addition, it was reported that conditional knockout of p65 or IKK β induces cell 483 
cycling of hematopoietic stem cells and increases their number (76) (77).  These 484 
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observations suggest that inhibition of the NF-κB pathway is one potential cause of 485 
the SET-Nup214-induced differentiation block of hematopoietic progenitor cells 486 
observed in SET-Nup214 transgenic mice.  Furthermore, it was previously 487 
demonstrated that the differentiation of U937 was inhibited by the expression of 488 
SET-Nup214 (23).  Similarly, the differentiation of U937 was inhibited by the 489 
presence of IKKβ inhibitor (78) (79).  These results also suggest that the inhibition 490 
of the NF-κB pathway by SET-Nup214 is, at least in part, a potential cause of U937 491 
differentiation block induced by SET-Nup214. 492 
In conclusion, SET-Nup214 and DEK-Nup214 interact with NTRs, and the 493 
interaction of either SET-Nup214 or DEK-Nup214 with XPO1 leads to a malfunction 494 
of transcription regulation by NF-κB.  Until now, many proteins have been identified 495 
as XPO1 cargos (80) (81).  In addition to IκBα and cyclin B1, these various cargos 496 
might accumulate in the nucleus of the case in which either SET-Nup214 or 497 
DEK-Nup214 is present.  In fact, β-catenin was reported to accumulate in the 498 
nucleus of set-nup214 transgenic mouse (21).  Because appropriate 499 
nuclear-cytoplasmic transport is required to cellular integrity, these localization 500 
disturbances of various proteins may synergistically lead to oncogenesis by 501 
SET-Nup214 and DEK-Nup214.  To know which NES proteins are responsible for 502 
SET-NUP214- and DEK-Nup214-mediated oncogenesis, comprehensive post-genome 503 
type analyses are required. 504 
  505 
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Figure legends  830 
Figure 1 Interaction between SET-Nup214 and DEK-Nup214 proteins and NTRs.  831 
(A) Schematic representation of SET-Nup214, DEK-Nup214, Nup214 (1057-2090), 832 
and SET-Nup214 (1637) used in our study and full length Nup214.  Box with 833 
vertical bars, SET portion; box with black dots, DEK portion; gray box, FG repeat 834 
region.  (B) HEK293T cells cultured in 6-well plates were transfected with 1 μg of 835 
pCHA-nuclear transport receptors (NTRs) or pCAGGS and 1 μg of 836 
pCAGGS-SET-Nup214-3Flag, DEK-Nup214-3Flag, or 3Flag-Nup214 (1057-2090).  837 
At two days after transfection, cells were collected and subjected to IP assays with 838 
300 ng of anti-HA (3F10) High Affinity antibody (Roche Diagnostics GmbH), and 839 
immunocomplexes were recovered by nProtein A Sepharose Fast Flow (GE 840 
Healthcare UK Ltd.).  After IP assays, proteins in input lysates and 841 
immunoprecipitated samples were separated by 6% SDS-PAGE, and western blot 842 
analyses were performed using anti-Flag M2 (2 μg/ml) (Sigma-Aldrich Co. LLC), and 843 
anti-HA (3F10) (1:1000) antibodies.  Prestained molecular weight markers (kDa) 844 
(Nacalai tesque, Inc., Japan) are indicated in the left.  (C) HEK293T cells cultured in 845 
10-cm dishes were transfected with 5 μg of pCAGGS, SET-Nup214-3Flag, 846 
DEK-Nup214-3Flag, 3Flag-Nup214 (1057-2090), and 3Flag-SET-Nup214 (1637).  847 
At two days after transfection, cells were collected, and cell lysates were subjected to 848 
immunoprecipitation with anti-Flag M2 Agarose Affinity Gel (Sigma-Aldrich Co. 849 
LLC.).  Proteins in input lysates and immunoprecipitated samples were separated by 850 
6.5%SDS-PAGE, and western blot analyses were performed using anti-Flag, 851 
anti-XPO1 (H-300) (1:1000) (Santa Cruz Biotechnology, Inc.), anti-NXF1 (53H8, 852 
Santa Cruz Biotechnology, Inc.) (1:500), and anti-β-actin (AC-15, Sigma-Aldrich Co. 853 
LLC) (1:5000) antibodies.  Prestained molecular weight markers (kDa) are indicated 854 
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in the left.  (D, E) HeLa cells cultured in 35-mm dishes were transfected with pCHA, 855 
HA-SET-Nup214, HA-DEK-Nup214, HA-Nup214 (1057-2090), and 856 
HA-SET-Nup214 (1637).  At two days after transfection, cells were subjected to IF 857 
assays.  For primary antibody, anti-HA (3F10) (1:100) (D), anti-XPO1 (1:20) (D), 858 
anti-HA rabbit (1:500) (E), and anti-NXF1 (1:20) (E) antibodies were used.  Right 859 
graphs represent relative intensities of HA-tagged protein and XPO1 (D) or NXF1 (E) 860 
along a line.  Bar: 10 μm. 861 
 862 
Figure 2 Dependency of NES proteins on complex and dot formation of either 863 
SET-Nup214 or DEK-Nup214 with XPO1.  (A) HeLa cells cultured in 35-mm 864 
dishes were transiently transfected with 1 μg of either pCAGGS-SET-Nup214-3Flag 865 
(SET-N214), DEK-Nup214-3Flag (DEK-N214), or pCAGGS.  At two days after 866 
transfection, cells were incubated in 5 ng/ml LMB (L-6100, LC Laboratories) for 0 867 
and 6 h.  After incubation, cells were collected, and subjected to IP assays using 868 
FLAG M2 beads (lanes 6 to 13). Proteins in input lysate and immunoprecipitated 869 
samples were separated by 6.5% SDS-PAGE, and western blot analyses were 870 
performed using anti-FLAG, anti-XPO1 antibodies as primary antibodies.  871 
Prestained molecular weight markers (kDa) are indicated in the left.  (B) Protocol 872 
was the same as one for Figure 2A.  After cells were collected, IF analyses were 873 
performed.  For primary antibody, anti-Flag M2 (1:1000) and anti-XPO1 antibodies 874 
were used.  Right graphs represent relative intensities of Flag-tagged protein and 875 
XPO1 along a line.  Bar: 20 μm. 876 
 877 
Figure 3 Localization of endogenous proteins harboring NES and mRNA.  (A) 878 
(Pictures) HeLa cells were transiently transfected with pCHA-SET-Nup214 or 879 
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HA-DEK-Nup214, and subjected to IF assays using anti-HA (3F10), anti-IκBα (C-21, 880 
Santa Cruz Biotechnology, Inc.) (1:100) or anti-p65 (PC137, Calbiochem) (1:100) 881 
antibodies.  (Graphs) Fluorescence intensity was quantitatively determined using 882 
ImageJ software.  Nuclear and cytoplasmic areas were selected manually. X 883 
axis=mean (intensity of HA-tagged protein in the nucleus)-mean(background), and Y 884 
axis=N/C=(mean(intensity of IκBα or p65 in the nucleus)-mean (background))/(mean 885 
(intensity of IκBα or p65 in the cytoplasm)-mean(background)).  (B) 293T cells were 886 
transfected with pCHA, HA-SET-Nup214, HA-DEK-Nup214, HA-Nup214 887 
(1057-2090), HA-SET-Nup214 (1637).  Two days later, cells were subjected to 888 
immunofluorescence assay using anti-HA (3F10) and anti-IκBα (L35A5, CST, Inc.) 889 
(1:20) antibodies. Fluorescence intensities of nuclear IκBα and HA-tagged protein in 890 
each sample were quantitatively determined using ImageJ software and plotted.  Bar: 891 
20 μm.  (C) HeLa cells were transiently transfected with pCHA-SET-Nup214 or 892 
DEK-Nup214, and subjected to IF assays using anti-HA (3F10), and anti-cyclinB1 893 
(4138, CST Inc.) (1:20) antibodies.  Fluorescence intensity of nuclear cyclin B1 in 894 
each cell was quantitatively determined using ImageJ software and plotted.  Bar: 20 895 
μm.  *P < 0.005, **P < 0.0005.  (D) HeLa cells were transiently transfected with 896 
pCAGGS, SET-Nup214-3Flag, or DEK-Nup214-3Flag, and subjected to IF assays 897 
using anti-Flag M2, and in situ hybridization assay with 10 ng/μl biotinylated oligo 898 
dT45 or oligo dA45 as probes.  In the dot plots, fluorescence intensity was quantified 899 
using ImageJ software as described in Figure 3A.  Bar: 10 μm. 900 
 901 
Figure 4 Decreased mobility of XPO1.  (A) HEK293T cells cultured in 35-mm 902 
dishes were transiently transfected with 1 μg pHCF1 (XPO1-EGFP expression vector), 903 
pmKate2C-SET-Nup214, and pmKate2C-DEK-Nup214.  Samples were separated by 904 
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5% SDS-PAGE and subjected to western blot analyses using anti-Nup214 (1:1000), 905 
anti-XPO1, and anti-C23 (D6, Santa Cruz Biotechnology, Inc.) (1:1000) antibodies.  906 
Prestained molecular weight markers (kDa) are indicated in the left.  (B, C) HeLa 907 
cells were transfected with 1 μg pHCF1, and 1 μg pmKate2C, 908 
pmKate2C-SET-Nup214, or pmKate2C-DEK-Nup214 and subjected to FRAP assays 909 
(C) as previously described (82).  Typical localization patterns of EGFP-XPO1, 910 
mKate2, mKate2-SET-Nup214, and mKate2-DEK-Nup214 are shown in (B).  Bar: 911 
10 μm. 912 
 913 
Figure 5 Effects of SET-Nup214 and DEK-Nup214 on NF-κB transcription 914 
activity.  (A-C) HEK293T cells (3x104) cultured in 24-well plates were transfected 915 
with pNF-κB40-firefly luciferase (10 ng), and pCAGGS-SET-Nup214 (SET-N214) or 916 
DEK-Nup214 (DEK-N214) (10, 100 ng).  pTA-Renilla luciferase (100 ng) was 917 
co-transfected for normalization of transfection efficiency.  At two days after 918 
transfection, cells were incubated with 1 ng/ml (lane 6 in left graphs and lane 7 in 919 
right graphs) or 5 ng/ml LMB (lane 7 in left graphs and lane 8 in right graphs) for 30 920 
min.  Then, recombinant human TNF-α (300-01A, PeproTech) was added, at the 921 
final concentration as 20 ng/ml (lanes 2-8 in right graphs), incubated for 3-4 h, and 922 
cell lysates were subjected to luciferase assays using Dual-Luciferase Reporter Assay 923 
System (Promega) according to manufacturer’s instructions.  Luminescence was 924 
measured by CentroXS3 LB960 (Berthold Japan K.K.).  Relative luciferase activity 925 
of the firefly luciferase activity (A), Renilla luciferase activity (B), and normalized 926 
luciferase activity (C) were expressed as fold activation relative to lane 1.  Data are 927 
presented as the mean ± SD of three independent experiments.  P value was 928 
calculated with lane 1 (left graph) or lane 2 (right graph).  *P < 0.05, **P < 0.005, 929 
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***P < 0.001.  Western blot analyses were performed using lysate prepared for 930 
luciferase assays in the presence of TNF-α.  Anti-Nup214 and anti-C23 antibodies 931 
were used as primary antibodies.  Prestained molecular weight markers (kDa) are 932 
indicated in the left.  (D) HEK293T cells (3x105) cultured in 6-well plates were 933 
transfected with pCAGGS-SET-Nup214 (SET-N214) or DEK-Nup214 (DEK-N214) 934 
(100, 1000 ng).  At two days after transfection, cells were incubated with 5 ng/ml 935 
LMB (lane 7) for 30 min, and TNF-α was added at the final concentration as 20 ng/ml 936 
(lanes 2-7).  After TNF-α incubation for 3-4 h, cells were collected, and isolated 937 
RNAs were subjected to RT-qPCR to measure A20 and IκBα mRNAs.  These 938 
mRNA expression levels were normalized to the level of β-actin mRNA and shown as 939 
fold inhibition relative to lane 2.  Data are presented as the mean ± SD of three 940 
independent experiments.  P value was calculated with lane 2.  *P < 0.05, 941 
**P < 0.005, ***P < 0.001. 942 
 943 
Figure 6 Interaction of p65 with IκBα or chromatin in the nucleus.  (A) HeLa 944 
cells cultured in 6-cm dishes were transfected with 2 μg pCHA, HA-SET-Nup214 945 
(SET-N214), or HA-DEK-Nup214 (DEK-N214). At two days after transfection, cells 946 
were collected, and subjected to IF assays and PLA.  Anti-p65 (ab7970, Abcam) 947 
(1:100) and anti-IκBα (L35A5, CST, Inc.) (1:30) antibodies were used for primary 948 
antibodies.  Merged is a composite picture stained with Alexa 488, Detection 949 
Reagents Red (for PLA), and Alexa 633.  Bar: 10 μm.  (B) HEK293T cells were 950 
transfected with pCAGGS, pCAGGS-SET-Nup214 (SN214), 951 
pCAGGS-DEK-Nup214 (DN214) (0.2, 2 μg), and incubated for 2 days. Cells were 952 
collected, and IP assays were conducted using anti-p65 (ab7970) and rabbit IgG 953 
polyclonal antibodies (PP64B) (Merck KGaA, Germany).  Proteins in input lysates 954 
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and immunoprecipitated samples were separated by 10% or 5% SDS-PAGE, and 955 
western blot analyses were performed using anti-p65, anti-IκBα, anti-Nup214, and 956 
anti-C23 antibodies.  Molecular weights (kDa) of prestained markers are indicated in 957 
the right.  (C) HEK293T cells were transfected with 5 μg pCAGGS, 958 
pCAGGS-SET-Nup214 (SET-N214), or pCAGGS-DEK-Nup214 (DEK-N214).  At 959 
two days after transfection, cells were treated with or without TNF-α (20 ng/ml) for 960 
30 min, and then subjected to ChIP assays using 2 μg anti-IgG or anti-p65 (ab7970) 961 
antibodies to measure p65 binding to A20 and IκBα promoter regions.  The 962 
immunoprecipitated DNA levels were normalized to the input DNA level and shown 963 
as fold activation relative to immunoprecipitated DNA from pCAGGS-transfected 964 
lysates by anti-p65 antibody in the absence of TNFα.  Data are presented as the 965 
mean ± SD of three independent experiments.  *P < 0.05. 966 
 967 
Figure 7 Interaction of p65 with IκBα or chromatin in the presence of stimuli.  968 
(A) HeLa cells were transfected with 1 μg of pCHA, HA-SET-Nup214, or 969 
HA-DEK-Nup214.  At two days after transfection, cells were treated with TNF-α 970 
(10 ng/ml) 30 min, and IF assays were performed using anti-HA rabbit and anti-IκBα 971 
(L35A5) antibodies.  Fluorescence intensity of nuclear IκBα in control cells, 972 
SET-Nup214 expressing cells, and DEK-Nup214 expressing cells was quantitatively 973 
determined using ImageJ software.  Bar: 20 μm.  ***P < 0.001.  (B) The protocol 974 
was the same as one for Figure 7A.  After incubation with anti-p65 (ab7970) and 975 
anti-IκBα (L35A5), PLA were performed.  Merged is a composite picture stained 976 
with Alexa 488, Detection Reagents Red (for PLA), and Alexa 633.  Sum of 977 
fluorescence intensity of PLA dots in each cell was quantitated using ImageJ software.  978 
Bar: 10 μm.  **P < 0.005, ***P < 0.001.  (C) HEK293T cells were transfected with 979 
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1 μg pCAGGS, pCAGGS-SET-Nup214 (SN214), pCAGGS-DEK-Nup214 (DN214) 980 
(0.2, 2 μg).  At two days after transfection, cells were treated with TNF-α (20 ng/ml) 981 
30 min, collected, and IP assays were conducted using anti-p65 (ab7970) and rabbit 982 
IgG polyclonal antibodies.  Proteins in input lysates and immunoprecipitated 983 
samples were separated by 12.5% or 5% SDS-PAGE, and western blot analyses were 984 
performed using anti-p65, anti-IκBα, anti-Nup214, and anti-C23 antibodies.  985 
Molecular weights (kDa) of prestained markers are indicated in the right.  (D) 986 
HEK293T cells were transfected with 2 μg pCAGGS, pCAGGS-SET-Nup214 987 
(SET-N214), or pCAGGS-DEK-Nup214 (DEK-N214).  At two days after 988 
transfection, cells were treated with or without TNF-α (20 ng/ml) for 60 min, and 989 
then subjected to ChIP assays same as Figure 6C.  Left graph represents the typical 990 
example and the right graph represents fold inhibition relative to immunoprecipitated 991 
DNA from pCAGGS-transfected lysates by anti-p65 antibody in the presence of 992 
TNF−α.  Right graphs are presented as the mean ± SD of three independent 993 
experiments.  *P < 0.05, **P < 0.01. 994 
 995 
Figure 8 Subcellular localization of XPO1, IκBα, and p65 in spleen of set-nup214 996 
transgenic mice.  Spleen sections of wild-type BDF1 and set-nup214 transgenic 997 
mice (lines G79 and G593) were subjected to IF assays.  Anti-SET/TAF-Iβ 998 
(KM1721) (1:20) (A), anti-XPO1 (1:100) (A), anti-Nup214 (1:100) (B, C), anti-IκBα 999 
(L35A5) (1:20) (B), and anti-p65 (F6) (1:20) (C), antibodies were used as primary 1000 
antibodies.  Merged is a composite picture stained with Alexa 488, Alexa 568, and 1001 
TOPRO-3.  Bar: 5 μm (A, C), 10 μm (B). 1002 
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